Compile Data Set for Download or QSAR
Report error Found 288 Enz. Inhib. hit(s) with all data for entry = 8614
TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404241((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-4'-(N-met...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404236((2S,5R)-1-(2'-chloro-5'-cyano-[1,1'-biphenyl]-4-ca...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403773((2S,5R)-5-(2-chlorophenyl)-1-(4'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404237((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-4'-(trifluo...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403786((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenetho...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404240((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-3'-(N-meth...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404231((2S,5R)-1-(2'-cyano-4'-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403752((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403763((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403764((2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoy...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403767((2S,5R)-5-(2-chlorophenyl)-1-(2'-fluoro-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404228((2S,5R)-5-(2,3-difluorophenyl)-1-(2'-methoxy-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404229((2S,5R)-5-(2,5-difluorophenyl)-1-(2'-methoxy-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404254((2S,5R)-1-(5'-cyano-2'-methyl-[1,1'-biphenyl]-4-ca...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404212((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-4'-methoxy-...)
Affinity DataKi: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404249((2S,5R)-5-(2-fluorophenyl)-1-(2'-methyl-3'-(N-meth...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404251((2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404253((2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2,4-dimethoxy...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404245((2S,5R)-1-(2'-cyano-4'-(trifluoromethyl)-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404247((2S,5R)-1-(2'-chloro-5'-cyano-[1,1'-biphenyl]-4-ca...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404248((2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408766(US10358416, Compound 385 | (2S,5R)-1-(1-(5-chloro-...)
Affinity DataKi: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403853((2S,5R)-5-(2-chlorophenyl)-1-(2',5'-dichloro-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403834((2S,5R)-5-(2-chlorophenyl)-1-(6-(2-chlorophenyl)ni...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403879((2S,5R)-5-(2-chlorophenyl)-1-(3'-(methylsulfonamid...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403881((2S,5R)-5-(2-chlorophenyl)-1-(4-(naphthalen-2-yl)b...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403868((2S,5R)-1-(4'-chloro-[1,1'-biphenyl]-4-carbonyl)-5...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403869((2S,5R)-1-(3'-chloro-[1,1'-biphenyl]-4-carbonyl)-5...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403873((2S,5R)-1-(2'-chloro-[1,1'-biphenyl]-4-carbonyl)-5...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403878((2S,5R)-5-(2-chlorophenyl)-1-(4'-(methylsulfonamid...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403865((2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxypyridin-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403866((2S,5R)-5-(2-chlorophenyl)-1-(4'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403907((2S,5R)-1-(4-benzylbenzoyl)-5-(2-chlorophenyl)pyrr...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403889((2S,5R)-5-(2-chlorophenyl)-1-(2'-isopropoxy-[1,1'-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403891((2S,5R)-5-(2-chlorophenyl)-1-(2'-(cyclopropylmetho...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403884((2S,5R)-5-(2-chlorophenyl)-1-(2'-(trifluoromethoxy...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403927((2S,5R)-5-(2-chlorophenyl)-1-(4-(3-methoxypyridin-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403909((2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403946((2S,5R)-1-(2'-chloro-2-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403949((2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methylthiophen-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403960((2S,5R)-5-(2-chlorophenyl)-1-(2',6'-dichloro-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403941((2S,5R)-5-(2-chlorophenyl)-1-(2',4'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403945((2S,5R)-1-(2-chloro-[1,1'-biphenyl]-4-carbonyl)-5-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403937((2S,5R)-5-(2-chlorophenyl)-1-(2'-(trifluoromethyl)...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403938((2S,5R)-5-(2-chlorophenyl)-1-(2,2'-dimethoxy-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403939((2S,5R)-1-(4'-chloro-2'-methoxy-[1,1'-biphenyl]-4-...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403931((2S,5R)-5-(2-chlorophenyl)-1-(2-methoxy-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403932((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-[1,1'-biphe...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403933((2S,5R)-5-(2-chlorophenyl)-1-(2',6'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403936((2S,5R)-5-(2-chlorophenyl)-1-(2',4'-dichloro-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

Displayed 1 to 50 (of 288 total ) | Next | Last >>
Jump to: